Clinical trials: Gastrointestinal Stromal Tumors
Neuroendocrine Tumor, Gastrointestinal Neoplasm
A Study of XmAb®18087 in Subjects With NET and GIST
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK…
- Trial name
- NCT03411915
- Testing
- XmAb18087
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Xencor, Inc.
Gastrointestinal Stromal Tumor
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works as first-line therapy in treating patients with…
- Trial name
- NCT00568750
- Testing
- dasatinib
- Where
- 18 sites in Finland, France and 2 more
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Gastrointestinal Stromal Tumors
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Trial name
- NCT00812240
- Testing
- Masitinib, Imatinib
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 335 people
- Sponsor
- AB Science
GIST, GIST, Malignant
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT (85%) or the PDGFRα (8%) protein.
- Conditions
- GIST, GIST, Malignant, PDGFR-Alpha D842V
- Trial name
- AVIATOR2020 (NCT04927260)
- Testing
- Patient treated by Avapritinib in real life
- Where
- 7 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Melanoma, Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
This was a phase 1, open-label, multiple dose, single-arm study. The mixed bacteria vaccine (MBV) was administered at a starting dose of 250 EU (1 µL) and escalated in each subject to a dose inducing the desired pyrogenic effect…
- Conditions
- Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer
- Trial name
- NCT00623831
- Testing
- Mixed bacterial vaccine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ludwig Institute for Cancer Research
GIST - Gastrointestinal Stromal Tumor
Ripretinib (QINLOCK®) According to Current SmPC
The goal of this prospective, observational study INTEREST is to collect real-world data on ripretinib treatment in a broad patient population in Germany. Ripretinib will be administered according to the current SmPC.
- Trial name
- INTEREST (NCT06619275)
- Testing
- Ripretinib
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- iOMEDICO AG
Gastrointestinal Stromal Tumor
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have unresectable…
- Trial name
- NCT00005597
- Testing
- temozolomide
- Where
- 106 sites in United States
- Volunteers
- 25 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Stromal Tumor (GIST)
Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)
Gastrointestinal stromal tumors (GIST) are the most common malignant sarcomas of the gastrointestinal tract. Inhibitors of the mutated driver proteins KIT and PDGFRA can temporarily control disseminated GIST disease but cannot…
- Trial name
- PATHFINDERS (NCT07109024)
- Testing
- Generation of a comprehensive and single-lesion resistance profile
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Universität Duisburg-Essen
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00112463
- Testing
- romidepsin
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and…
- Trial name
- NCT05905887
- Testing
- Rivoceranib Mesylate, Paclitaxel
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST)
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically…
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
- Trial name
- NCT05489237
- Testing
- IDRX-42
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 276 people
- Sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Gastrointestinal Stromal Tumors
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
- Trial name
- NCT00444795
- Testing
- Sunitinib malate
- Where
- 47 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
- Trial name
- NCT05381753
- Testing
- Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CStone Pharmaceuticals
Gastrointestinal Stromal Tumors
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
This is a extension study of CSTI571B1201 study
- Trial name
- NCT00237172
- Testing
- Imatinib Mesylate
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
This study will evaluate the efficacy and safety of nilotinib in gastrointestinal stromal tumors patients who failed imatinib and sunitinib therapy.
- Trial name
- NCT00718562
- Testing
- AMN107
- Where
- 8 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
GIST
Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
This is a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes.
- Trial name
- RetroGIST (NCT04599660)
- Testing
- Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)
- Where
- 13 sites in Italy
- Volunteers
- 700 people
- Sponsor
- Italian Sarcoma Group
Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumors (GIST) Registry
The goal of this observational research study is to establish a registry of information regarding how different physicians treat and manage patients with gastrointestinal stromal tumors (GISTs). Objectives: 1.
- Trial name
- NCT00507273
- Testing
- GIST Registry
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University